AR037341A1 - COMPOUNDS DERIVED FROM 1-OXA-ESPIRO [2,5] OCTAN-6-OL, METHOD OF SYNTHESIS OF COMPOUNDS DERIVED FROM FUMAGILINE, PHARMACEUTICAL AND COSMETIC COMPOSITIONS THAT INCLUDE THEM, USE OF PHARMACEUTICAL COMPOSITIONS AND USE OF COSMETIC COMPOSITION COSMETICS COMPOSITIONS - Google Patents
COMPOUNDS DERIVED FROM 1-OXA-ESPIRO [2,5] OCTAN-6-OL, METHOD OF SYNTHESIS OF COMPOUNDS DERIVED FROM FUMAGILINE, PHARMACEUTICAL AND COSMETIC COMPOSITIONS THAT INCLUDE THEM, USE OF PHARMACEUTICAL COMPOSITIONS AND USE OF COSMETIC COMPOSITION COSMETICS COMPOSITIONSInfo
- Publication number
- AR037341A1 AR037341A1 ARP020104286A ARP020104286A AR037341A1 AR 037341 A1 AR037341 A1 AR 037341A1 AR P020104286 A ARP020104286 A AR P020104286A AR P020104286 A ARP020104286 A AR P020104286A AR 037341 A1 AR037341 A1 AR 037341A1
- Authority
- AR
- Argentina
- Prior art keywords
- carbon atoms
- radical
- compositions
- linear
- formula
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 7
- 239000002537 cosmetic Substances 0.000 title abstract 7
- 239000000203 mixture Substances 0.000 title abstract 6
- 230000015572 biosynthetic process Effects 0.000 title abstract 2
- 238000000034 method Methods 0.000 title abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 238000003786 synthesis reaction Methods 0.000 title abstract 2
- NMRPBPVERJPACX-UHFFFAOYSA-N octan-3-ol Chemical compound CCCCCC(O)CC NMRPBPVERJPACX-UHFFFAOYSA-N 0.000 title 1
- 125000004432 carbon atom Chemical group C* 0.000 abstract 11
- -1 alkyl radical Chemical class 0.000 abstract 7
- 150000003254 radicals Chemical class 0.000 abstract 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 3
- 208000032544 Cicatrix Diseases 0.000 abstract 2
- 206010028980 Neoplasm Diseases 0.000 abstract 2
- 125000000217 alkyl group Chemical group 0.000 abstract 2
- 125000003118 aryl group Chemical group 0.000 abstract 2
- HGCIXCUEYOPUTN-UHFFFAOYSA-N cyclohexene Chemical compound C1CCC=CC1 HGCIXCUEYOPUTN-UHFFFAOYSA-N 0.000 abstract 2
- 208000035475 disorder Diseases 0.000 abstract 2
- 231100000241 scar Toxicity 0.000 abstract 2
- 230000037387 scars Effects 0.000 abstract 2
- AFANEXYKOPKSNB-UHFFFAOYSA-N 1-oxaspiro[2.5]octan-6-ol Chemical compound C1CC(O)CCC11OC1 AFANEXYKOPKSNB-UHFFFAOYSA-N 0.000 abstract 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 abstract 1
- 201000004384 Alopecia Diseases 0.000 abstract 1
- 208000003120 Angiofibroma Diseases 0.000 abstract 1
- 201000003076 Angiosarcoma Diseases 0.000 abstract 1
- 206010004146 Basal cell carcinoma Diseases 0.000 abstract 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 abstract 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 abstract 1
- 206010013786 Dry skin Diseases 0.000 abstract 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 abstract 1
- 208000010412 Glaucoma Diseases 0.000 abstract 1
- 208000001258 Hemangiosarcoma Diseases 0.000 abstract 1
- 208000007766 Kaposi sarcoma Diseases 0.000 abstract 1
- 208000002260 Keloid Diseases 0.000 abstract 1
- 201000004681 Psoriasis Diseases 0.000 abstract 1
- 206010037649 Pyogenic granuloma Diseases 0.000 abstract 1
- 206010038934 Retinopathy proliferative Diseases 0.000 abstract 1
- 241001303601 Rosacea Species 0.000 abstract 1
- 206010039710 Scleroderma Diseases 0.000 abstract 1
- 206010052779 Transplant rejections Diseases 0.000 abstract 1
- 101000927076 Xenopus laevis Apoptosis regulator R11 Proteins 0.000 abstract 1
- 230000032683 aging Effects 0.000 abstract 1
- 125000003342 alkenyl group Chemical group 0.000 abstract 1
- 230000033115 angiogenesis Effects 0.000 abstract 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 abstract 1
- 229910052794 bromium Inorganic materials 0.000 abstract 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 abstract 1
- 230000004663 cell proliferation Effects 0.000 abstract 1
- 229910052801 chlorine Inorganic materials 0.000 abstract 1
- 239000000460 chlorine Substances 0.000 abstract 1
- 206010012601 diabetes mellitus Diseases 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 230000037336 dry skin Effects 0.000 abstract 1
- QUPDWYMUPZLYJZ-UHFFFAOYSA-N ethyl Chemical group C[CH2] QUPDWYMUPZLYJZ-UHFFFAOYSA-N 0.000 abstract 1
- 208000024519 eye neoplasm Diseases 0.000 abstract 1
- 229910052731 fluorine Inorganic materials 0.000 abstract 1
- 239000011737 fluorine Substances 0.000 abstract 1
- 208000024963 hair loss Diseases 0.000 abstract 1
- 230000003676 hair loss Effects 0.000 abstract 1
- 125000005843 halogen group Chemical group 0.000 abstract 1
- 230000009931 harmful effect Effects 0.000 abstract 1
- 201000011066 hemangioma Diseases 0.000 abstract 1
- 230000001969 hypertrophic effect Effects 0.000 abstract 1
- 230000002757 inflammatory effect Effects 0.000 abstract 1
- 229910052740 iodine Inorganic materials 0.000 abstract 1
- 239000011630 iodine Substances 0.000 abstract 1
- 208000028867 ischemia Diseases 0.000 abstract 1
- 210000001117 keloid Anatomy 0.000 abstract 1
- 206010025135 lupus erythematosus Diseases 0.000 abstract 1
- 230000003211 malignant effect Effects 0.000 abstract 1
- 201000001441 melanoma Diseases 0.000 abstract 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 abstract 1
- WCYWZMWISLQXQU-UHFFFAOYSA-N methyl Chemical compound [CH3] WCYWZMWISLQXQU-UHFFFAOYSA-N 0.000 abstract 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 abstract 1
- 201000003142 neovascular glaucoma Diseases 0.000 abstract 1
- 201000008106 ocular cancer Diseases 0.000 abstract 1
- 230000003287 optical effect Effects 0.000 abstract 1
- 150000002924 oxiranes Chemical class 0.000 abstract 1
- 229910052760 oxygen Inorganic materials 0.000 abstract 1
- 238000011084 recovery Methods 0.000 abstract 1
- 230000002207 retinal effect Effects 0.000 abstract 1
- 201000003068 rheumatic fever Diseases 0.000 abstract 1
- 201000004700 rosacea Diseases 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 230000037390 scarring Effects 0.000 abstract 1
- 229910052717 sulfur Inorganic materials 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
- A61K8/4973—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with oxygen as the only hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D303/00—Compounds containing three-membered rings having one oxygen atom as the only ring hetero atom
- C07D303/02—Compounds containing oxirane rings
- C07D303/12—Compounds containing oxirane rings with hydrocarbon radicals, substituted by singly or doubly bound oxygen atoms
- C07D303/18—Compounds containing oxirane rings with hydrocarbon radicals, substituted by singly or doubly bound oxygen atoms by etherified hydroxyl radicals
- C07D303/20—Ethers with hydroxy compounds containing no oxirane rings
- C07D303/22—Ethers with hydroxy compounds containing no oxirane rings with monohydroxy compounds
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Dermatology (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Rheumatology (AREA)
- Ophthalmology & Optometry (AREA)
- Vascular Medicine (AREA)
- Transplantation (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Urology & Nephrology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Pain & Pain Management (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Birds (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Epoxy Compounds (AREA)
- Cosmetics (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Compuestos derivados de 1-oxa-espiro [2,5] octan-6-ol, que responden a la formula general (1), en la cual: Rx representa H, un radical alquilo lineal o ramificado de 1 a 5 átomos de carbono o un radical 1-hidroxialquilo lineal o ramificado de 1 a 5 átomos de carbono; R1 representa un radical alquilo lineal o ramificado de 1 a 5 átomos de carbono, o un radical alquenilo que tiene la estructura de fórmula (2) o el epóxido correspondiente representado por la estructura de la formula (3); R5 y R6 tienen las significaciones dadas anteriormente, R2 es H o un radical alquilo lineal de 1 a 5 átomos de carbono, R3 es H o un radical representado por las fórmulas (4) ó (5); R7 e Y tienen las significaciones dadas anteriormente; R4 es H, un radical alquilo lineal o ramificado de 1 a 5 átomos de carbono, o un radical XR11, R4 es preferentemente un radical metilo o etilo; X y R11 tienen las significaciones dadas anteriormente; R5 es H o un radical metilo; R6 es H o un radical alquilo lineal o ramificado de 1 a 5 átomos de carbono, los radicales R5 y R6 tomados en forma conjunta, pueden tomar un carbociclo de 3 a 10 átomos de carbono insaturado o no, como, por ejemplo, un ciclohexeno; R7 es una cadena poliinsaturada que presenta de 5 a 7 átomos de carbono y una función carboxilo terminal o un núcleo aromático correspondiente a la fórmula general (6); R8, R9, R10, valen independientemente H o OCH3, R11 es H, un radical alquilo de 1 a 5 átomos de carbono o un núcleo aromático; X representa O ó S; Y representa un átomo de halógeno elegido entre el cloro, el bromo, el yodo y el flúor, y se entiende que, cuando R2 representa un alquilo de 1 a 5 átomos de carbono y R4 representa H, entonces R1 representa un alquilo de 1 a 5 átomos de carbono o un alquenilo que tiene la estructura (a) y cuando R1 representa el radical (b) entonces Rx y R4 no pueden simultáneamente representar H, y los isómeros ópticos y geométricos, las sales así como las mezclas de dichos compuestos de fórmula (1). Método para la síntesis de compuestos derivados de fumagilina, composiciones farmacéuticas y cosméticas, utilización de las composiciones farmacéuticas y utilización cosmética de las composiciones cosméticas. Los compuestos de formula (1) son útiles por ejemplo para el tratamiento de las afecciones relacionadas con un desorden de la angiogénesis, con la proliferación celular, de carácter inflamatorio o no, tales como los hemangiomas, los tumores malignos o benignos, los cánceres, los melanomas, los carcinomas de las células basales, el granuloma piogénico, los angiofibromas, la esclerodermia, los tumores oculares, la isquemia coriorretiniana, los neovasos retinianos, el glaucoma neovascular, las cicatrices tracomatosas, las enfermedades reumatoides , la artritis reumática, la psoriasis, el sarcoma de Kaposi, el angiosarcoma, el lupus, la rosácea, la retinopatía proliferativa de origen diabético, el rechazo de injerto, los trastornos de la cicatrización tales como las queloides y las cicatrices hipertróficas. Los compuestos de fórmula (1) son también útiles en el campo cosmético, por ejemplo para la higiene corporal o capilar; para el tratamiento de las pieles con tendencia acneica, para la recuperación del cabello, contra la caída del cabello, para luchar contra el aspecto graso de la piel o del cabello, para la protección contra los efectos nefastos del sol o para el tratamiento de las pieles fisiológicamente secas, y para prevenir y/o luchar contra el envejecimiento fotoinducido o cronológico.Compounds derived from 1-oxa-spiro [2,5] octan-6-ol, which respond to the general formula (1), in which: Rx represents H, a linear or branched alkyl radical of 1 to 5 carbon atoms or a linear or branched 1-hydroxyalkyl radical of 1 to 5 carbon atoms; R1 represents a linear or branched alkyl radical of 1 to 5 carbon atoms, or an alkenyl radical having the structure of formula (2) or the corresponding epoxide represented by the structure of formula (3); R5 and R6 have the meanings given above, R2 is H or a linear alkyl radical of 1 to 5 carbon atoms, R3 is H or a radical represented by formulas (4) or (5); R7 and Y have the meanings given above; R4 is H, a linear or branched alkyl radical of 1 to 5 carbon atoms, or an XR11 radical, R4 is preferably a methyl or ethyl radical; X and R11 have the meanings given above; R5 is H or a methyl radical; R6 is H or a linear or branched alkyl radical of 1 to 5 carbon atoms, the radicals R5 and R6 taken together can take a carbocycle of 3 to 10 carbon atoms unsaturated or not, such as a cyclohexene ; R7 is a polyunsaturated chain having 5 to 7 carbon atoms and a carboxyl terminal function or an aromatic nucleus corresponding to the general formula (6); R8, R9, R10, independently worth H or OCH3, R11 is H, an alkyl radical of 1 to 5 carbon atoms or an aromatic nucleus; X represents O or S; Y represents a halogen atom chosen from chlorine, bromine, iodine and fluorine, and it is understood that when R2 represents an alkyl of 1 to 5 carbon atoms and R4 represents H, then R1 represents an alkyl of 1 to 5 carbon atoms or an alkenyl having the structure (a) and when R1 represents the radical (b) then Rx and R4 cannot simultaneously represent H, and the optical and geometric isomers, salts as well as mixtures of said compounds of Formula 1). Method for the synthesis of compounds derived from fumagiline, pharmaceutical and cosmetic compositions, use of pharmaceutical compositions and cosmetic use of cosmetic compositions. The compounds of formula (1) are useful, for example, for the treatment of conditions related to an angiogenesis disorder, with cellular proliferation, inflammatory or not, such as hemangiomas, malignant or benign tumors, cancers, melanomas, basal cell carcinomas, pyogenic granuloma, angiofibromas, scleroderma, ocular tumors, chorioretinal ischemia, retinal neovases, neovascular glaucoma, tracomatous scars, rheumatoid diseases, rheumatic arthritis, psoriasis , Kaposi's sarcoma, angiosarcoma, lupus, rosacea, proliferative retinopathy of diabetic origin, graft rejection, scarring disorders such as keloids and hypertrophic scars. The compounds of formula (1) are also useful in the cosmetic field, for example for body or hair hygiene; for the treatment of skins with acneic tendency, for the recovery of hair, against hair loss, to fight against the oily appearance of the skin or hair, for protection against the harmful effects of the sun or for the treatment of physiologically dry skin, and to prevent and / or fight against photoinduced or chronological aging.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR0114542A FR2832149B1 (en) | 2001-11-09 | 2001-11-09 | NOVEL INHIBITORS OF ANGIOGENESIS AND THEIR PHARMACEUTICAL AND COSMETIC USE |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR037341A1 true AR037341A1 (en) | 2004-11-03 |
Family
ID=8869256
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP020104286A AR037341A1 (en) | 2001-11-09 | 2002-11-08 | COMPOUNDS DERIVED FROM 1-OXA-ESPIRO [2,5] OCTAN-6-OL, METHOD OF SYNTHESIS OF COMPOUNDS DERIVED FROM FUMAGILINE, PHARMACEUTICAL AND COSMETIC COMPOSITIONS THAT INCLUDE THEM, USE OF PHARMACEUTICAL COMPOSITIONS AND USE OF COSMETIC COMPOSITION COSMETICS COMPOSITIONS |
Country Status (5)
| Country | Link |
|---|---|
| EP (1) | EP1480964A1 (en) |
| JP (1) | JP2005519026A (en) |
| AR (1) | AR037341A1 (en) |
| FR (1) | FR2832149B1 (en) |
| WO (1) | WO2003040119A1 (en) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2872511B1 (en) * | 2004-06-30 | 2006-08-11 | Galderma Res & Dev | NOVEL INHIBITORS OF ANGIOGENESIS AND THEIR PHARMACEUTICAL AND COSMETIC USE |
| US8299067B2 (en) * | 2008-03-27 | 2012-10-30 | Versitech Limited | 5-demethoxyfumagillol and derivatives thereof |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE68927904T2 (en) * | 1988-09-01 | 1997-09-04 | Takeda Chemical Industries Ltd | Fumagillol derivatives |
| DE68915900T2 (en) * | 1988-09-01 | 1994-11-24 | Childrens Medical Center | Angiogenesis inhibitor. |
| ATE87623T1 (en) * | 1989-03-06 | 1993-04-15 | Takeda Chemical Industries Ltd | 6-EPIFUMAGILLOLS, THEIR PREPARATION AND USE. |
| US6017954A (en) * | 1989-08-10 | 2000-01-25 | Children's Medical Center Corp. | Method of treating tumors using O-substituted fumagillol derivatives |
| AU719106B2 (en) * | 1995-02-28 | 2000-05-04 | Gillette Company, The | Use of angiogenesis suppressors for inhibiting hair growth |
| WO1998056372A1 (en) * | 1997-06-09 | 1998-12-17 | Massachusetts Institute Of Technology | TYPE 2 METHIONINE AMINOPEPTIDASE (MetAP2) INHIBITORS AND USES THEROF |
| WO1999061432A1 (en) * | 1998-05-12 | 1999-12-02 | Biochem Pharma Inc. | Fumagillin analogs and their use as angiogenesis inhibitors |
-
2001
- 2001-11-09 FR FR0114542A patent/FR2832149B1/en not_active Expired - Fee Related
-
2002
- 2002-10-29 WO PCT/FR2002/003721 patent/WO2003040119A1/en not_active Ceased
- 2002-10-29 JP JP2003542165A patent/JP2005519026A/en not_active Withdrawn
- 2002-10-29 EP EP02795355A patent/EP1480964A1/en not_active Withdrawn
- 2002-11-08 AR ARP020104286A patent/AR037341A1/en not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| JP2005519026A (en) | 2005-06-30 |
| FR2832149A1 (en) | 2003-05-16 |
| EP1480964A1 (en) | 2004-12-01 |
| WO2003040119A1 (en) | 2003-05-15 |
| WO2003040119A8 (en) | 2003-11-27 |
| FR2832149B1 (en) | 2006-01-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP4442241A3 (en) | Retinol replacement in skin treatment | |
| AR003220A1 (en) | ACILATED MELATONIN DERIVATIVES; PHARMACEUTICAL AND COSMETIC COMPOSITION AND THE USE OF THE SAME FOR THE PREPARATION OF A MEDICINAL PRODUCT. | |
| FI950255A0 (en) | Extensible absorbent structure | |
| PA8604301A1 (en) | USED 2-AMINO-PYRIDINE DERIVATIVES FOR THE TREATMENT OF DISEASES | |
| ES2154858T3 (en) | PHOTOSTABILIZED FILTER COSMETIC COMPOSITIONS THAT INCLUDE A DIBENZOYLMETHANE DERIVATIVE AND AN AMIDED COMPOUND. | |
| AR009643A1 (en) | ANTIMICROBIAL COMPOSITIONS FOR PERSONAL CARE | |
| NO334695B1 (en) | Use of idebenone for the protection of cosmetic and dermatological preparations | |
| PA8604201A1 (en) | USED 2-AMINO-PYRIDINE DERIVATIVES FOR THE TREATMENT OF DISEASES | |
| ATE411317T1 (en) | INDOLE-3-CARBINOL METABOLITES AS CHEMOTHERAPEUTIC AND CHEMOPREVENTIVE AGENTS | |
| ES2153862T3 (en) | PARENTERAL ADMINISTRATION BISULFAN FOR THE TREATMENT OF MALIGNAL DISEASES. | |
| BR112018069405A2 (en) | substituted non-alpha peroxyacids and their use | |
| UY28317A1 (en) | USEFUL COMPOUNDS FOR THE TREATMENT OF DISEASES | |
| CA2780025C (en) | Dermatological compositions comprising a fat or oil of an essential fatty acid triglyceride | |
| AR037341A1 (en) | COMPOUNDS DERIVED FROM 1-OXA-ESPIRO [2,5] OCTAN-6-OL, METHOD OF SYNTHESIS OF COMPOUNDS DERIVED FROM FUMAGILINE, PHARMACEUTICAL AND COSMETIC COMPOSITIONS THAT INCLUDE THEM, USE OF PHARMACEUTICAL COMPOSITIONS AND USE OF COSMETIC COMPOSITION COSMETICS COMPOSITIONS | |
| DE60016181D1 (en) | C-16 UNSATURATED FP-SELECTIVE PROSTAGLANDIN ANALOG | |
| KR960700213A (en) | Anti-androgenic cyclo- and bicyclo alkenes | |
| RU2012153186A (en) | CAROTINOID SUN PROTECTOR | |
| CN111405890A (en) | Composition for preventing or improving intrinsic aging containing paeoniflorin or paeonolide | |
| AR050103A1 (en) | COMPOSITION | |
| CN102846599B (en) | Topical composition | |
| FR2455609A1 (en) | 24-24-DIFLUORO-25-HYDROXYCHOLECALCIFEROL | |
| DK1699468T3 (en) | Pharmaceutical composition comprising a zinc hyaluronate complex for the treatment of disseminated skeletal rose | |
| IT7826263A0 (en) | DERIVATIVES OF PYRANOCROMONE AND THERAPEUTIC COMPOSITION INCLUDING THE SAME, FOR THE TREATMENT OF ALLERGIC DISEASES. | |
| ES2196645T3 (en) | TRANSPARENT COMPOSITIONS FOR SKIN CARE. | |
| Jacobs et al. | Vasodilatory adverse events associated with topical imiquimod 5 percent cream |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |